Abstract
Background: Mucormycosis, commonly referred to as 'black fungus,' has arisen as a complication associated with COVID-19. Objectives: This research investigated the clinical features, demographic profiles, and outcomes of patients with mucormycosis during the COVID-19 pandemic. Methods: A case series involving 29 patients diagnosed with mucormycosis was conducted. The study systematically examined demographic information, underlying health conditions, COVID-19 status, and clinical outcomes of these patients. Results: The majority of patients, accounting for 90%, developed mucormycosis subsequent to COVID-19 infection, with diabetes mellitus being the predominant comorbidity, affecting 38% of cases. A higher incidence was observed in males, and the mortality rate was significant. Functional endoscopic sinus surgery (FESS) was utilized for both diagnosis and treatment, although the success rate of this procedure varied. Conclusions: Post-COVID-19 mucormycosis presents intricate clinical challenges, particularly in patients with comorbidities and weakened immune systems. Prompt diagnosis and a comprehensive, multidisciplinary approach are crucial. Additional research is needed to enhance our comprehension and improve treatment strategies for this daunting infection.